A Translational Quantitative Systems Pharmacology Model for CD3 Bispecific Molecules: Application to Quantify T Cell-Mediated Tumor Cell Killing by P-Cadherin LP DART®
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1550-7416
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
A Translational Quantitative Systems Pharmacology Model for CD3 Bispecific Molecules: Application to Quantify T Cell-Mediated Tumor Cell Killing by P-Cadherin LP DART® ; volume:21 ; number:4 ; day:22 ; month:5 ; year:2019 ; pages:1-16 ; date:7.2019
The AAPS journal / American Association of Pharmaceutical Scientists ; 21, Heft 4 (22.5.2019), 1-16, 7.2019
- Urheber
-
Betts, Alison
Haddish-Berhane, Nahor
Shah, Dhaval K.
Graaf, Piet H. van der
Barletta, Frank
King, Lindsay
Clark, Tracey
Kamperschroer, Cris
Root, Adam
Hooper, Andrea
Chen, Xiaoying
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1208/s12248-019-0332-z
- URN
-
urn:nbn:de:101:1-2019111413204089349954
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:23 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Betts, Alison
- Haddish-Berhane, Nahor
- Shah, Dhaval K.
- Graaf, Piet H. van der
- Barletta, Frank
- King, Lindsay
- Clark, Tracey
- Kamperschroer, Cris
- Root, Adam
- Hooper, Andrea
- Chen, Xiaoying
- SpringerLink (Online service)
Ähnliche Objekte (12)
Bispecific antibodies promote natural killer cell-mediated elimination of HIV-1 reservoir cells
Bispecific antibody-activated T cells enhance NK cell-mediated antibody-dependent cellular cytotoxicity
T-cell stimulating vaccines empower CD3 bispecific antibody therapy in solid tumors
CD33/CD3-bispecific T-cell engaging (BiTE®) antibody construct targets monocytic AML myeloid-derived suppressor cells
CD33/CD3-bispecific T-cell engaging (BiTE®) antibody construct targets monocytic AML myeloid-derived suppressor cells
Inhibition of T cell-mediated inflammation in uveitis by a novel anti-CD3 antibody
Engineered allogeneic T cells decoupling T-cell-receptor and CD3 signalling enhance the antitumour activity of bispecific antibodies
A gB/CD3 bispecific BiTE antibody construct for targeting Human Cytomegalovirus-infected cells
Molecular insights into recognition of GUCY2C by T-cell engaging bispecific antibody anti-GUCY2CxCD3
T-cell surveillance of therapy-induced senescent lymphoma cells in the presence of anti-CD19/CD20 × CD3 bispecific antibodies
A novel asymmetrical anti-HER2/CD3 bispecific antibody exhibits potent cytotoxicity for HER2-positive tumor cells
AFM13: a first-in-class tetravalent bispecific anti-CD30/CD16A antibody for NK cell-mediated immunotherapy
Bispecific antibodies promote natural killer cell-mediated elimination of HIV-1 reservoir cells
Bispecific antibody-activated T cells enhance NK cell-mediated antibody-dependent cellular cytotoxicity
T-cell stimulating vaccines empower CD3 bispecific antibody therapy in solid tumors
CD33/CD3-bispecific T-cell engaging (BiTE®) antibody construct targets monocytic AML myeloid-derived suppressor cells
CD33/CD3-bispecific T-cell engaging (BiTE®) antibody construct targets monocytic AML myeloid-derived suppressor cells
Inhibition of T cell-mediated inflammation in uveitis by a novel anti-CD3 antibody
Engineered allogeneic T cells decoupling T-cell-receptor and CD3 signalling enhance the antitumour activity of bispecific antibodies
A gB/CD3 bispecific BiTE antibody construct for targeting Human Cytomegalovirus-infected cells
Molecular insights into recognition of GUCY2C by T-cell engaging bispecific antibody anti-GUCY2CxCD3
T-cell surveillance of therapy-induced senescent lymphoma cells in the presence of anti-CD19/CD20 × CD3 bispecific antibodies
A novel asymmetrical anti-HER2/CD3 bispecific antibody exhibits potent cytotoxicity for HER2-positive tumor cells
AFM13: a first-in-class tetravalent bispecific anti-CD30/CD16A antibody for NK cell-mediated immunotherapy
Bispecific antibodies promote natural killer cell-mediated elimination of HIV-1 reservoir cells
Bispecific antibody-activated T cells enhance NK cell-mediated antibody-dependent cellular cytotoxicity
T-cell stimulating vaccines empower CD3 bispecific antibody therapy in solid tumors
CD33/CD3-bispecific T-cell engaging (BiTE®) antibody construct targets monocytic AML myeloid-derived suppressor cells
CD33/CD3-bispecific T-cell engaging (BiTE®) antibody construct targets monocytic AML myeloid-derived suppressor cells
Inhibition of T cell-mediated inflammation in uveitis by a novel anti-CD3 antibody
Engineered allogeneic T cells decoupling T-cell-receptor and CD3 signalling enhance the antitumour activity of bispecific antibodies
A gB/CD3 bispecific BiTE antibody construct for targeting Human Cytomegalovirus-infected cells
Molecular insights into recognition of GUCY2C by T-cell engaging bispecific antibody anti-GUCY2CxCD3
T-cell surveillance of therapy-induced senescent lymphoma cells in the presence of anti-CD19/CD20 × CD3 bispecific antibodies
A novel asymmetrical anti-HER2/CD3 bispecific antibody exhibits potent cytotoxicity for HER2-positive tumor cells